Table of Contents
non-MRSA organisms
beta lactamase resistant penicillins
cephalosporins
other antibiotics
MRSA organisms
vancomycin intermediate-resistant Staphylococcus aureus (VISA)
antibiotics for Rx of Staph. aureus
see also:
antibiotics
staphylococcus
wikipedia - MRSA
non-MRSA organisms
beta lactamase resistant penicillins
flucloxacillin
dicloxacillin
methicillin
penicillins combined with beta lactamase inhibitors such as clavulanic acid, sulbactam, tazobactam
eg.
amoxycillin
with clavulanic acid (Augmentin Duo Forte)
cephalosporins
cephalexin
cephazolin
other antibiotics
erythromycin
quinolones such as ciprofloxacin
MRSA organisms
MRSA contains a gene, mecA, which stops β-lactam antibiotics from inactivating the enzymes (transpeptidases) that are critical to cell wall synthesis
use of fluoroquinolones is associated with significantly increased risk of colonisation with MRSA
community acquired MRSA is a hybrid of hospital MRSA and community Staph and tends to be more virulent, although easier to treat than hospital MRSA
CA-MRSA may respond to co-trimoxazole, tetracyclines or clindamycin but is usually treated with vancomycin
vancomycin
teicoplanin
a structural congener of vancomycin that has a similar activity spectrum but a longer half-life
vancomycin intermediate-resistant Staphylococcus aureus (VISA)
linezolid
quinupristin/dalfopristin(synercid)
daptomycin
This antibiotic is not effective for left-sided endocarditis, or for pneumonia because it binds to surfactant and is inactivated.
The efficacy of daptomycin in patients with prosthetic heart valves has not been demonstrated.
see also
Australian Prescriber article
tigecycline